SYDNEY AUSTRALIA (June 22, 2023) - The prevalence and impact of mental health in Australia represents a genuine crisis. 1 in 5 Australians experience mental illness in any year, while over 40% of Australians will experience a mental illness in their lifetime. Psychedelic-assisted therapy clinic GoodMind Therapeutics has commenced registering patients nationwide for eligibility checks and intends to start treatments later this year with a clear mission in mind:
“To provide new treatment options for the millions of Australians that suffer from mental health conditions. Our goal is to help individuals overcome their challenges and live more meaningful, fulfilling lives. We believe that psychedelic-assisted therapy can be a powerful tool in achieving this goal, and we are proud to be a part of this emerging field of work and to actively contribute to the body of clinical psychedelic research.”
The GoodMind clinic offers:
The latest advances in psychedelic medicine with leading evidence-based care, in a supported and integrated psychotherapy experience
A specialised treatment centre offering MDMA-assisted therapy for the treatment of PTSD, and
Psilocybin-assisted therapy for treatment-resistant depression
Therapeutic dosing in a carefully controlled medical setting
Nationwide patient registration for treatment eligibility assessment
Treatments to commence later this year
GoodMind is backed by a multidisciplinary team who are experts in their fields and trained in psychedelic-assisted therapy, supporting patients through their treatment journey. The safety and effectiveness of psychedelic therapies depends on a unique set of professional competencies, which the GoodMind team brings to the table.
Dr John Barlow, Research Lead and Principal Investigator, commented: “Emerging evidence on the efficacy of psychedelic-assisted therapy provides new treatment options for those in need. The results of research to date have been compelling enough to warrant further exploration, with trials globally offering evidence for the potential use in cases of psychedelic therapy in helping treat a number of conditions including depression, PTSD, end-of-life distress, alcohol use disorder, and nicotine dependence.
The role of psychedelics in psychedelic-assisted therapy is to induce a profound altered state of consciousness, which can lead to increased introspection, emotional openness, and changes in perception and thought patterns. Psychedelics should also be administered in combination with supportive therapy and a controlled environment. Together with Dr Joanne Shannon, Psychiatrist and Co-Investigator, we look forward to pushing the boundaries of current knowledge in this space in order to discover positive therapeutic outcomes”.
Scott Kelly, Founding Psychologist, added that: “The experience made available through the therapeutic use of psychedelics, along with music and psychotherapy, presents a profound opportunity for healing and well-being to those who have not been helped by conventional methods. The embodied and holistic nature of psychedelic-assisted psychotherapy allows people to dive deep and explore profound aspects of themselves within the safety of a supportive therapeutic relationship. I believe that it is this combination of the psychedelic experience with comprehensive psychotherapy that has led to the promising results in the current research”.
John Pitchford, Chief Executive Officer and Co-Founder, concluded:
“We are excited to announce the launch of our new, ground-breaking company, GoodMind Therapeutics. As one of the first companies in Australia to officially recognise the potential of the combination of psychedelics and psychotherapy for the treatment of mental illnesses, we are proud to be at the forefront of psilocybin and MDMA treatment. Our team of highly skilled and experienced experts have worked tirelessly to develop safe and effective treatment plans for patients. We are committed to providing the highest possible level of safety, as well as compassionate care to people who have not responded well to other treatments.
This new and pioneering approach has shown promising results thus far, and gives us the potential to revolutionise mental health care. We believe that our approach offers a new and accessible option to those experiencing mental illnesses. At GoodMind, we are dedicated to working towards making a real difference to people's lives”.
Available for comment:
John Pitchford, Chief Executive Officer and Co-Founder
Dr John Barlow, Research Lead and Principal Investigator
Scott Kelly, Founding Psychologist
For interested patients, clinicians or investors: https://goodmindtherapeutics.com.au/contact-us/
For more information: https://goodmindtherapeutics.com.au/
AJD Media, email@example.com 0459034092 or 0412372158